(Q30768601)

26 June 2017

1 reference

title

Fenofibrate in the treatment of dyslipidemia: a review of the data as they relate to the new suprabioavailable tablet formulation (English)

1 reference

26 June 2017

1 reference

Jadwiga Najib

1

1 reference

26 June 2017

language of work or name

1 reference

1 December 2002

1 reference

26 June 2017

published in

Clinical Therapeutics

1 reference

26 June 2017

volume

24

1 reference

26 June 2017

issue

12

1 reference

26 June 2017

page(s)

2022-2050

1 reference

AHA Dietary Guidelines: revision 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association

26 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

The West of Scotland Coronary Prevention Study: a trial of cholesterol reduction in Scottish men.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Clinical pharmacokinetics of fibric acid derivatives (fibrates).

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Micronized fenofibrate: a new fibric acid hypolipidemic agent

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Review of European clinical experience with fenofibrate

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

1 reference

7 January 2021

Micronised fenofibrate

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Modification of metabolism and distribution of lipids by ethyl chlorophenoxyisobutyrate

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Structure and biochemical effects of fenofibrate

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Pharmacology of fenofibrate

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Safety of fenofibrate--US and worldwide experience

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Effect of fenofibrate treatment on plasma lipoprotein lipids, high-density lipoprotein cholesterol subfractions, and apolipoproteins B, AI, AII, and E.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Drug treatment of lipid disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Fibrates and triglyceride metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Potential use of fenofibrate and other fibric acid derivatives in the clinic

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Fibric acids: effects on lipids and lipoprotein metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Effect of fibric acid derivatives on blood lipid and lipoprotein levels

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Mechanism of action of the nongenotoxic peroxisome proliferators: role of the peroxisome proliferator-activator receptor alpha.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Mechanism of action of fibrates on lipid and lipoprotein metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Fenofibrate affects the compositions of lipoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Effect of clofibrate on postheparin plasma triglyceride lipase activities in patients with hypertriglyceridemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Transcriptional control of triglyceride metabolism: fibrates and fatty acids change the expression of the LPL and apo C-III genes by activating the nuclear receptor PPAR.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

The fibrates in clinical practice: focus on micronised fenofibrate

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

The biochemical pharmacology of fenofibrate

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Effect of hemodialysis on plasma kinetics of fenofibrate in chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Variations in lipids and proteins of lipoproteins by fenofibrate in some hyperlipoproteinaemic states

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Long-term effects of fenofibrate on serum lipids and on lipoprotein cholesterol in type II hyperlipoproteinemic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Effect of fenofibrate on serum lipoproteins in subjects with familial hypercholesterolemia and combined hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Effect of fenofibrate treatment on type III hyperlipoproteinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Long term-effect of fenofibrate on lipoprotein level and composition in different types of genetic hyperlipidemias

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Fenofibrate therapy of hyperlipoproteinaemia a dose—response study and a comparison with clofibrate

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Effects of fenofibrate on plasma lipids. Double-blind, multicenter study in patients with type IIA or IIB hyperlipidemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Fenofibrate in type IV and type V hyperlipoproteinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Hypertriglyceridemia and hyperuricemia: effects of two fibric acid derivatives (bezafibrate and fenofibrate) in a double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Bezafibrate and fenofibrate in type II diabetics with hyperlipoproteinaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Pharmacodynamic activity of lipoprotein lipase and hepatic lipase, and pharmacokinetic parameters measured in normolipidaemic subjects receiving ciprofibrate (100 or 200 mg/day) or micronised fenofibrate (200 mg/day) therapy for 23 days.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Changes in lipoprotein kinetics during therapy with fenofibrate and other fibric acid derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Fenofibrate and colestipol: effects on serum and lipoprotein lipids and apolipoproteins in familial hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Low-dose colestipol plus fenofibrate: effects on plasma lipoproteins, lecithin:cholesterol acyltransferase, and postheparin lipases in familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Safety, tolerability, and efficacy of simvastatin and fenofibrate--a multicenter study. Simvastatin-Fenofibrate Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIA or IIB hyperlipoproteinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Effects of simvastatin and fenofibrate on serum lipoproteins and apolipoproteins in primary hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Effect of simvastatin and fenofibrate on the fatty acid composition of hypercholesterolaemic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

A multicenter comparison of the effects of simvastatin and fenofibrate therapy in severe primary hypercholesterolemia, with particular emphasis on lipoproteins defined by their apolipoprotein composition

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Lipoprotein particle analysis comparing simvastatin and fenofibrate

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Efficacy and safety of a new hydroxymethylglutaryl-coenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: comparison with fenofibrate.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Comparison of the efficacy of atorvastatin and micronized fenofibrate in the treatment of mixed hyperlipidemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Effectiveness and safety of alternate-day simvastatin and fenofibrate on mixed hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Cost effectiveness of micronised fenofibrate and simvastatin in the short-term treatment of type IIa and type IIb hyperlipidaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Diabetic dyslipidemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Diabetes, hyperlipidemia, and coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Benefits of micronised Fenofibrate in type 2 diabetes mellitus subjects with good glycemic control

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Baseline characteristics of the study population in the Diabetes Atherosclerosis Intervention Study (DAIS). World Health Organization Collaborating Centre for the Study of Atherosclerosis in Diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Diabetes Atherosclerosis Intervention Study (DAIS): quantitative coronary angiographic analysis of coronary artery atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Interaction between fenofibrate and warfarin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Pharmacokinetics of cyclosporine in hyperlipidaemic long-term survivors of heart transplantation. Lack of interaction with the lipid-lowering agent, fenofibrate

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Drug interactions with grapefruit: whose responsibility is it to warn the public?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

A review of combined hyperlipidaemia and its treatment with fenofibrate

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Treatment of hypercholesterolaemia with fenofibrate: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Effects of fibric acid derivatives on biliary lipid composition

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Effects of fenofibrate and gemfibrozil on plasma homocysteine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Fenofibrate raises plasma homocysteine levels in the fasted and fed states

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Serum homocysteine increases after therapy with fenofibrate or bezafibrate

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

Fenofibrate decreases plasma fibrinogen, improves lipid profile, and reduces uricemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980095-9

7 January 2021

10.1016/S0149-2918(02)80095-9

Identifiers

DOI

1 reference

26 June 2017

1 reference